HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Todd Rosengart Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rosengart, T. Search for Related Content PubMed Articles by Rosengart, T. Related Collections Related Article

Ann Thorac Surg 2000;70:2118
© 2000 The Society of Thoracic Surgeons

Invited commentary

^a Division of Cardiothoracic Surgery, Evanston Northwestern Healthcare, Northwestern University Medical School, 2650 Ridge Ave, Evanston, IL 60201, USA

e-mail: trosengart@enh.org

A growing number of experimental studies continue to strengthen the evidence base suggesting the feasibility of administering angiogenic growth factor as a means of "biologically" revascularizing ischemic tissues. This strategy, termed therapeutic angiogenesis, has now been shown to induce the neovascularization of a wide variety of tissues. A number of studies, including this report by Sato and associates, suggest that this neovascularization response to growth factor delivery is sufficiently robust to . . . [Full Text of this Article]

Related Article

Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia

Kaori Sato, Roger J. Laham, Justin D. Pearlman, Deborah Novicki, Frank W. Sellke, Michael Simons, and Mark J. Post
Ann. Thorac. Surg. 2000 70: 2113-2118. [Abstract] [Full Text] [PDF]